Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: DAP3 expression was related with poor prognosis in public datasets: (A) Relative DAP3 expression levels across TCGA, GEO, and ICGC datasets. (B) Survival curves derived from TCGA datasets. (C) Survival curves based on ICGC datasets. (D) Univariate Cox regression analysis for overall survival in HCC. (E) Multivariate Cox regression analysis related to overall survival in HCC. (F) DAP3 expression in various pan-cancers using TIMER2.0 datasets. (G) DAP3 expression in various HCC subtypes using UALCAN datasets. (H) Overall survival analysis across pan-cancers. (I) Survival curves in CESC, KIRC, and KIRP. *P<0.05, **P<0.01, ***P<0.001, ****P < 0.0001.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques: Expressing, Derivative Assay

Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: Correlation between DAP3 and immune-related functions in HCC: (A) Immune cell infiltration in low and high DAP3 expression groups based on TIMER scores. (B) Immune cell infiltration in low and high DAP3 expression groups based on CIBERSORT scores. (C) Immune cell infiltration in low and high DAP3 expression groups based on MCP-counter scores. (D) Proportional plot illustrating the relationship between DAP3 expression and responder numbers based on TIDE scores. (E) Predicted immune response and tumor microenvironment characteristics in low and high DAP3 expression groups. (F) Expression levels of immune checkpoint genes in low and high-risk groups. *P<0.05,**P<0.01,***P<0.001.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: The potential role of DAP3 in HCC genomic alterations: (A) Classification and frequency of gene mutations. (B) Waterfall plot depicting gene mutations in the high-DAP3 expression group. (C) Waterfall plot illustrating gene mutations in the low-DAP3 expression group. (D) DAP3 expression levels and genomic alterations in low versus high DAP3 expression groups. (E) Distribution of copy number variations (CNVs) across different chromosomal regions in the high-DAP3 expression group. (F) Distribution of CNVs across different chromosomal regions in the low-DAP3 expression group. **P<0.01, ***P<0.001.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: A single-cell expression atlas and the identification of DAP3 in HCC by scRNA-seq: (A) Distribution of various cell types in hepatocellular carcinoma (HCC). (B) Comparison of cell type distribution in adjacent liver and tumor tissues. (C) Top five marker genes for different cell types. (D) Expression levels of DAP3 across various cell types. (E) Expression and distribution of DAP3 in adjacent liver tissues. (F) Expression and distribution of DAP3 in tumor tissues. (G) Comparison of gene expression levels in different cell types within tumor tissues versus adjacent tissues. (H) Gene expression levels in different cell types during recurrence compared to non-recurrence conditions.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques: Expressing, Comparison, Marker, Gene Expression

Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: Increased DAP3 expression was associated with poor prognosis in HCC patients: (A) Relative DAP3 expression levels in HCC tissues as measured by qRT-PCR (n = 71). (B) DAP3 expression analyzed via Western blot in HCC tissues (n = 4). (C) Representative images of DAP3 expression in HCC tissues obtained through immunohistochemical staining (magnification: 40X; scale bar: 100 μm). (D) IHC scores for DAP3 expression. (E) ROC curve analysis of DAP3 expression and AFP value. (F) Overall survival (OS) time compared using Kaplan–Meier analysis. ***P<0.001.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Immunohistochemical staining, Staining

Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: Correlation of DAP3 expression with clinicopathological characteristics in HCC patients.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: Univariate and multivariate Cox regression analyses related to overall survival in patients with HCC.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques:

Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: Knockdown of DAP3 inhibited the progression of HCC cells: (A) DAP3 expression levels in normal hepatocytes (LO2) compared to five HCC cell lines. (B) Knockdown efficiency in HCCLM3 cells confirmed by qRT-PCR. (C) Knockdown efficiency in HCCLM3 cells validated by Western blot. (D) CCK-8 assay results in DAP3-knockdown HCCLM3 cells. (E) Colony formation assay conducted in DAP3-knockdown HCCLM3 cells. (F) Number of colonies formed in DAP3-knockdown HCCLM3 cells. (G) Representative images from migration and invasion assays in DAP3-knockdown HCCLM3 cells. (H) Number of migrated or invaded cells in DAP3-knockdown HCCLM3 cells. (I) Apoptosis levels in DAP3-knockdown HCCLM3 cells. (J) Apoptotic rates in DAP3-knockdown HCCLM3 cells. *P<0.05,**P<0.01,***P<0.001,****P<0.0001.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques: Knockdown, Expressing, Quantitative RT-PCR, Western Blot, CCK-8 Assay, Colony Assay, Migration

Journal: Frontiers in Immunology

Article Title: Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

doi: 10.3389/fimmu.2025.1528853

Figure Lengend Snippet: Overexpression of DAP3 promoted the progression of HCC cells: (A) Overexpression efficiency in SK-Hep1 cells confirmed by qRT-PCR. (B) Overexpression efficiency in SK-Hep1 cells validated by Western blot. (C) CCK-8 assay results in DAP3-overexpressing SK-Hep1 cells. (D) Colony formation assay conducted in DAP3-overexpressing SK-Hep1 cells. (E) Number of colonies formed in DAP3-overexpressing SK-Hep1 cells. (F) Representative images from migration and invasion assays in DAP3-overexpressing SK-Hep1 cells. (G) Number of migrated or invaded cells in DAP3-overexpressing SK-Hep1 cells. (H) Apoptosis levels in DAP3-overexpressing SK-Hep1 cells. (I) Apoptotic rates in DAP3-overexpressing SK-Hep1 cells. (J) Volcano plot shown the co-expressed protein with DAP3 in HCC. (K) Correlation analysis between DAP3, FLAD1, HAX1, and NDUFS2 based on GEPIA datasets. *P<0.05, **P<0.01, ***P<0.001.

Article Snippet: The antibodies used for Western blot were as follows: anti-GAPDH antibody (1:20000, Proteintech, China), anti-DAP3 antibody (1:200, Santa Cruz, China), HRP-conjugated-β-actin antibody (1:5000, Proteintech, China) and HRP-conjugated goat anti-mouse IgG antibody (1:1000, Beyotime, China).

Techniques: Over Expression, Quantitative RT-PCR, Western Blot, CCK-8 Assay, Colony Assay, Migration

Journal: Journal of Xenobiotics

Article Title: The Unique Capability of Endolysin to Tackle Antibiotic Resistance: Cracking the Barrier

doi: 10.3390/jox15010019

Figure Lengend Snippet: Comparison of the selected phage endolysins.

Article Snippet: Endolysin , 266 , vB_BceM_AP3_0015 , Burkholderia phage AP3 , E. coli, K. pneumoniae, P. aeruginosa, B. cenocepacia, S. enterica, Staphylococcus aureus and S. epidermidis , Both , In vitro , None , YES , ATCC , pEXP5-CT/TOPO , Escherichia coli BL21-AI , pH 3–10 , 10–55 °C , [ ] .

Techniques: Comparison, Activity Assay, Bacteria, Animal Model, Expressing, Plasmid Preparation, In Vitro